<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035450</url>
  </required_header>
  <id_info>
    <org_study_id>C338</org_study_id>
    <nct_id>NCT01035450</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial</brief_title>
  <acronym>RESET</acronym>
  <official_title>Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent
      is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion
      revascularization at 1-year and death or myocardial infarction at 3-year after stent
      implantation in the real world clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sirolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan.
      Everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved
      in the first quarter of 2010 by the Japanese Ministry of Health, Labor and Welfare. It has
      recently been reported that everolimus-eluting stent had lower rate of target-lesion
      revascularization and stent thrombosis at 1 year as compared with paclitaxel-eluting stent.
      However, trial results comparing everolimus-eluting stent with sirolimus-eluting stent are
      largely unknown. The purpose of this study is to evaluate whether the newly-approved
      everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate
      of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year
      after stent implantation in the real world clinical practice. The design of this study is
      all-comer design enrolling patients scheduled for percutaneous coronary intervention using
      drug-eluting stents without any exclusion criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>all-cause death or myocardial infarction</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis (Academic Research Consortium definition)</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic and hemorrhagic strokes excluding transient ischemic attacks and secondary causes</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications (GUSTO and TIMI definition)</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent deployment success</measure>
    <time_frame>at implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure time</measure>
    <time_frame>at implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically-driven target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary artery bypass grafting</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any repeat coronary revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of cardiac death, myocardial infarction in the territory of the target vessel or target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of all-cause death, any myocardial infarction or any repeat coronary revascularization</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3206</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <description>Everolimus-eluting stent</description>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent</intervention_name>
    <description>Sirolimus-eluting stent</description>
    <arm_group_label>Sirolimus-eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for percutaneous coronary intervention using drug-eluting stents

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

